Leishmania enzymes and ribosomes

Leishmania enzymes and ribosomes represent a broad collective of molecular targets essential for the survival, replication, and pathogenesis of Leishmania protozoa, the causative agents of leishmaniasis. Key enzymatic targets include trypanothione reductase, which is unique to trypanosomatids and critical for maintaining redox balance against host-derived oxidative bursts (Fairlamb & Cerami, 1992, PMID: 1550335). Other vital enzymes include sterol 14-alpha-demethylase (CYP51), involved in ergosterol biosynthesis, and DNA topoisomerases required for genomic integrity (McCall et al., 2013, PMID: 23755111). The Leishmania ribosome is a primary target for aminoglycosides like paromomycin, which binds to the decoding A-site of the small ribosomal subunit, inducing mistranslation and subsequent parasite death (Fernández et al., 2011, PMID: 21944577). While these targets offer pathways for selective toxicity, the development of effective therapeutics is often hampered by significant host toxicity of current drugs and the rapid emergence of resistant parasite strains (Sunyoto et al., 2018, PMID: 30145157). This entry is categorized as incorrect because it groups multiple distinct molecular entities rather than identifying a single specific therapeutic target.

Other names

Leishmanial metabolic enzymesLeishmania protein synthesis machineryLeishmania drug targetsKinetoplastid enzymes and ribosomes

Inhibition of protein synthesis by binding to the 18S ribosomal RNA (Paromomycin); Inhibition of trypanothione reductase leading to lethal oxidative stress (Antimonials); Disruption of sphingolipid metabolism and cell signaling (Miltefosine); Inhibition of sterol 14-alpha-demethylase (Azoles); Inhibition of DNA topoisomerase IB (Camptothecin derivatives).